What is Illumina's (ilmn) stock price potential in the next year?
Illumina (NASDAQ: ILMN) is a giant in the world of next-generation sequencing (NGS). The first chart breaks down the global market for next-generation sequencing -- …
Where can I buy Illumina Inc (ilmn)?
Apr 03, 2022 · Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ILMN stock has increased by 47.4% and is now trading at $362.68. View which stocks have been most impacted by COVID-19.
Who holds Illumina's stock?
Get the latest Illumina, Inc. (ILMN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Who sold ilmn stock in the last quarter?
Real time Illumina (ILMN) stock price quote, stock graph, news & analysis.
Is ILMN stock a buy or sell?
Out of 8 analysts, 3 (37.5%) are recommending ILMN as a Strong Buy, 0 (0%) are recommending ILMN as a Buy, 4 (50%) are recommending ILMN as a Hold, 0 (0%) are recommending ILMN as a Sell, and 1 (12.5%) are recommending ILMN as a Strong Sell.
Is ILMN overvalued?
In conclusion, the stock of Illumina (NAS:ILMN, 30-year Financials)is believed to be modestly overvalued. The company's financial condition is fair and its profitability is strong. Its growth ranks worse than 73% of the companies in the industry of Medical Diagnostics & Research.Mar 26, 2021
How do I buy ILMN stock?
How to buy Illumina Stocks & Shares to Invest in ILMN Steps of buying Illumina sharesStep 1: find a good online broker. ... Step 2: open your brokerage account. ... Step 3: deposit money to your account. ... Step 4: buy the Illumina share. ... Step 5: review your Illumina position regularly.
Does ILMN stock pay dividends?
ILLUMINA (NASDAQ: ILMN) does not pay a dividend.
Is Illumina undervalued?
Relative to the current share price of US$380, the company appears quite undervalued at a 31% discount to where the stock price trades currently.Jan 21, 2022
Is Ilmn a good stock to buy?
Illumina is still a bargain right now. According to my valuation, the intrinsic value for the stock is $551.26, but it is currently trading at US$356 on the share market, meaning that there is still an opportunity to buy now.Feb 2, 2022
Can I invest in Illumina?
Invest in Illumina Inc on Stash. Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. , you can buy Illumina Inc stock in any dollar amount, or any other fund or stock you know on Stash.
Who does Illumina sell to?
Illumina acquired Epicentre Biotechnologies, based in Madison, Wisconsin, on January 11, 2011. On January 25, 2012, Hoffmann-La Roche made an unsolicited bid to buy Illumina for $44.50 per share or about $5.7 billion. Roche tried other tactics, including raising its offer (to $51.00, for about $6.8 billion).
Is Illumina a buy right now?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 7 hold rati...
How has Illumina's stock been impacted by COVID-19 (Coronavirus)?
Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organ...
When is Illumina's next earnings date?
Illumina is scheduled to release its next quarterly earnings announcement on Tuesday, April 26th 2022. View our earnings forecast for Illumina .
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Thursday, February, 10th. The life sciences company reported $0.75 earnings per share f...
What guidance has Illumina issued on next quarter's earnings?
Illumina updated its FY 2022 earnings guidance on Monday, February, 28th. The company provided earnings per share guidance of $4.000-$4.200 for the...
What price target have analysts set for ILMN?
10 brokerages have issued twelve-month target prices for Illumina's stock. Their forecasts range from $340.00 to $480.00. On average, they expect I...
Who are Illumina's key executives?
Illumina's management team includes the following people: Francis A. deSouza , President, Chief Executive Officer & Director Robert P. Ragusa ,...
What is Francis deSouza's approval rating as Illumina's CEO?
496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com . Francis deSouza has an approval rating of 92% among Illumina's employees....
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Thermo Fisher Scientific (TMO) , Agilent Technologies (A) , Mettler-Toledo International (MT...
About Illumina
Headlines
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function.
Illumina (NASDAQ:ILMN) Frequently Asked Questions
Illumina vs. Qiagen: Which Diagnostics & Research Stock is a Better Buy?
Nasdaq Global Select
10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Illumina stock.
Environmental, Social, and Governance Rating
The company develops, manufactures, and markets next-generation life-science tools and integrated systems to analyze genetic variations and biological functions.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Signals & Forecast
The company develops, manufactures, and markets next-generation life-science tools and integrated systems to analyze genetic variations and biological functions.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Friday, February 18, 2022, and so far it has risen 5.62%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices.
Is Illumina stock A Buy?
Illumina finds support from accumulated volume at $319.86 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are negative selling more shares than they are buying in Illumina
Illumina holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About Illumina
In the last 100 trades there were 74.31 thousand shares bought and 110.04 thousand shares sold. The last trade was done 5 days ago by Hoyt Aimee L who sold 3.42 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Golden Star Signal
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The companys sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Illumina (ILMN)
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Illumina, Inc. - Hold
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
